University Cardiology Department, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
University Cardiology Department, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Clin Chim Acta. 2015 Mar 30;443:39-47. doi: 10.1016/j.cca.2014.06.028. Epub 2014 Jul 5.
A great body of evidence has shown that extracellular matrix (ECM) alterations are present in the major types of cardiac diseases: ischemic heart disease, heart disease associated with pressure overload, heart disease associated with volume overload, and intrinsic myocardial disease or cardiomyopathy. Collagen, type I and III, is the principal structural protein found in the myocardium and its pro- or telopeptides are released into the circulation during the course of cardiovascular diseases. Therefore, these peptides may reflect collagen synthesis and break-down and also represent a much more useful tool to address ECM changes from a distance. Clinical trials have been performed during recent years to examine the usage of these peptides as diagnostic or prognostic biomarkers in heart failure (HF) patients. This review aims to summarize published data concerning cardiac ECM and its circulating biomarkers. Studies that focused on collagen metabolism related biomarkers in patients with HF are analyzed. Finally, limitations associated with the clinical use of the aforementioned biomarkers are also discussed.
大量证据表明，细胞外基质 (ECM) 的改变存在于主要类型的心脏疾病中：缺血性心脏病、与压力超负荷相关的心脏病、与容量超负荷相关的心脏病以及内在的心肌疾病或心肌病。I 型和 III 型胶原是心肌中主要的结构蛋白，其前肽或 telopeptides 在心血管疾病过程中释放到循环中。因此，这些肽段可能反映胶原的合成和分解，也代表了一种更有用的工具，可以从远处评估 ECM 的变化。近年来进行了临床试验，以检查这些肽段作为心力衰竭 (HF) 患者的诊断或预后生物标志物的用途。本综述旨在总结有关心脏 ECM 及其循环生物标志物的已发表数据。分析了专注于 HF 患者胶原代谢相关生物标志物的研究。最后，还讨论了上述生物标志物临床应用的局限性。
